A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1455-1465

  Locher, Christopher P ^a   Jones, Steven M ^a   Hanzelka, Brian L ^a   Perola, Emanuele ^a   Shoen, Carolyn M ^a   Cynamon, Michael H ^b   Ngwane, Andile H ^c   Wiid, Ian J ^c   Van Helden, Paul D ^c   Betoudji, Fabrice ^d   Nuermberger, Eric L ^d   Thomson, John A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b Central New York Research Corporation   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIKACIN; AMINOBENZIMIDAZOLE; AMINOBENZIMIDAZOLE PRODRUG; BCG VACCINE; BEDAQUILINE; BENZIMIDAZOLE DERIVATIVE; BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; CLOFAZIMINE; DIMETHYL SULFOXIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ISONIAZID; LINEZOLID; MACROGOL 400; MOXIFLOXACIN; PRETOMANID; PRODRUG; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TOCOFERSOLAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; GYRASE INHIBITOR; VXC-486;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BCG VACCINATION; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GROWTH INHIBITION; LUNG BURDEN; MOUSE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; HUMAN; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS; TOPOISOMERASE II INHIBITORS;

EID: 84923218792     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04347-14     Document Type: Article

References (33)

1. World Health Organization. 2014. Global tuberculosis report 2014. WHO, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.
2. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 41:101-106.
3. Mdluli K, Ma Z. 2007. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 7:159-168. http://dx.doi.org/10.2174/187152607781001763.
4. Kale MG, Raichurkar A, Hameed S, , Waterson D, McKinney D, Manjunatha MR, Kranthi U, Koushik K, Jena L, Shinde V, Rudrapatna S, Barde S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Ghosh A, Ramya VK, Guptha S, Sharma S, Vachaspati P, Kumar KN, Giridhar J, Reddy J, Panduga V, Ganguly S, Ahuja V, Gaonkar S, Kumar CN, Ogg D, Tucker JA, Boriack-Sjodin PA, de Sousa SM, Sambandamurthy VK, Ghorpade SR. 2013. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. J Med Chem 56:8834-8848. http://dx.doi.org/10.1021/jm401268f.
5. Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sharma S, Nandishaiah R, Mahesh Kumar KN, Ganguly S, Ahuja V, Gaonkar S, Naveen Kumar CN, Ogg D, Boriack-Sjodin PA, Sambandamurthy VK, de Sousa SM, Ghorpade SR. 2014. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. Bioorg Med Chem Lett 24:870-879. http://dx.doi.org/10.1016/j.bmcl.2013.12.080.
6. Shirude PS, Madhavapeddi P, Tucker JA, Murugan K, Patil V, Basavarajappa H, Raichurkar AV, Humnabadkar V, Hussein S, Sharma S, Ramya VK, Narayan CB, Balganesh TS, Sambandamurthy VK. 2013. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. ACS Chem Biol 8:519-523. http://dx.doi.org/10.1021/cb300510w.
7. Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE. 2013. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold ofATPcompetitive dual targeting type II topoisomerase inhibiting antibacterial agents. J Med Chem 56:8712-8735. http://dx.doi.org/10.1021/jm401208b.
8. Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Nelson K, Brown-Driver V, Castellano A, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Finn J, Tari LW. 2013. Pyrrolopyrimidine inhibitors ofDNAgyrase B (GyrB) and topoisomerase IV (ParE). Part II. Development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Bioorg Med Chem Lett 23:1537-1543. http://dx.doi.org/10.1016/j.bmcl.2012.11.073.
9. Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J. 2013. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. PLoS One 8:e84409. http://dx.doi.org/10.1371/journal.pone.0084409.
10. Jeankumar VU, Renuka J, Kotagiri S, Saxena S, Kakan SS, Sridevi JP, Yellanki S, Kulkarni P, Yogeeswari P, Sriram D. 2014. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues. ChemMed-Chem 9:1850-1859. http://dx.doi.org/10.1002/cmdc.201402035.
11. Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. 2008. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51:5243-5263. http://dx.doi.org/10.1021/jm800318d.
12. Grossman TH, Bartels DJ, Mullin S, Gross CH, Parsons JD, Liao Y, Grillot AL, Stamos D, Olson ER, Charifson PS, Mani N. 2007. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 51:657-666. http://dx.doi.org/10.1128/AAC.00596-06.
13. Grillot A-L, Le Tiran A, Shannon D, Krueger E, Liao Y, O'Dowd H, Tang Q, Ronkin S, Wang T, Waal N, Li P, Lauffer D, Sizensky E, Tanoury J, Perola E, Grossman TH, Doyle T, Hanzelka B, Jones S, Dixit V, Ewing N, Liao S, Boucher B, Jacobs M, Bennani Y, Charifson PS.. 2014. Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability. J Med Chem 57: 8792-8816. http://dx.doi.org/10.1021/jm500563g.
14. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Muller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, David van Helden P, Victor TC, Trollip AP. 2013. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 19:449-455. http://dx.doi.org/10.3201//EID1903.120246.
15. Mani N, Gross CH, Parsons JD, Hanzelka B, Muh U, Mullin S, Liao Y, Grillot AL, Stamos D, Charifson PS, Grossman TH. 2006. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 50:1228-1237. http://dx.doi.org/10.1128/AAC.50.4.1228-1237.2006.
16. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36:362-366.
17. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1380-1385. http://dx.doi.org/10.1128/AAC.00055-06.
18. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44:688-692. http://dx.doi.org/10.1128/JCM.44.3.688-692.2006.
19. Becton Dickinson and Company. 1999. Bactec MGIT 960 system user's manual, catalog number 445876. Becton Dickinson and Company, Franklin Lakes, NJ.
20. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. http://dx.doi.org/10.1124/pr.58.3.10.
21. Heifets LB. 1996. Clinical mycobacteriology. Drug susceptibility testing. Clin Lab Med 16:641-656.
22. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53:4178-4184. http://dx.doi.org/10.1128/AAC.00830-09.
23. Shoen CM, DeStefano MS, Sklaney MR, Monica BJ, Slee AM, Cynamon MH. 2004. Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 53:641-645. http://dx.doi.org/10.1093/jac/dkh124.
24. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 72:1065-1071. http://dx.doi.org/10.1128/IAI.72.2.1065-1071.2004.
25. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.AmJ Resp Crit Care Med 180:1151-1157. http://dx.doi.org/10.1164/rccm.200905-0795OC.
26. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Resp Crit Care Med 184:732-737. http://dx.doi.org/10.1164/rccm.201103-0397OC.
27. Chopra S, Matsuyama K, Tran T, Malerich JP, Wan B, Franzblau SG, Lun S, Guo H, Maiga MC, Bishai WR, Madrid PB. 2012. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother 67:415-421. http://dx.doi.org/10.1093/jac/dkr449.
28. Hameed S, Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, RM, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V. 2014. Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother 58:4993-4994. http://dx.doi.org/10.1128/AAC.03463-14.
29. Rullas J, Garcia JI, Beltran M, Cardona PJ, Caceres N, Garcia-Bustos JF, Angulo-Barturen I. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54: 2262-2264. http://dx.doi.org/10.1128/AAC.01423-09.
30. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. 2014. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 9:e94462. http://dx.doi.org/10.1371/journal.pone.0094462.
31. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 1241:48-70. http://dx.doi.org/10.1111/j.1749-6632.2011.06330.x.
32. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK. 2014. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother 58:495-502. http://dx.doi.org/10.1128/AAC.01903-13.
33. Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy VK, Rodrigues C, Hoffner S. 2014. In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:4222-4223. http://dx.doi.org/10.1128/AAC.02718-14.